WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 11, 548-560. Review Article ISSN 2277–7105

FETAL GENETIC DISORDERS IN PREGNANCY: A COMPARATVE STUDY OF TREATMENT IN INDIA VS OTHER COUNTRIES

M. Vinothini*, B. Prethika, V. Ajay, G. P. Jothika, S. Senthilkumar, S. Parthasarathi

India.

Article Received on 05 May 2026,
Article Revised on 25 May 2026,
Article Published on 01 June 2026,

https://doi.org/10.5281/zenodo.20439375

***Corresponding Author**
M. Vinothini
India.

How to cite this Article: M. Vinothini*, B. Prethika, V. Ajay, G. P. Jothika, S. Senthilkumar, S. Parthasarathi. (2026). Fetal Genetic Disorders In Pregnancy: A Comparatve Study Of Treatment In India Vs Other Countries. Effect. World Journal of Pharmaceutical Research, 15(11), 548–560.

ABSTRACT

Fetal genetic disorders are a major cause of congenital anomalies and neonatal morbidity worldwide. Advances in prenatal diagnostic techniques such as ultrasonography, non-invasive prenatal testing (NIPT), amniocentesis, and chorionic villus sampling have improved early detection and management of fetal abnormalities. This review compares the diagnosis, treatment, and prevention strategies for fetal genetic disorders in India and developed countries. In India, management mainly focuses on genetic counseling, prenatal screening, and selective termination due to limited access to advanced fetal therapies. Developed countries, however, have established specialized fetal medicine centers and advanced interventions including in-utero surgery, stem cell therapy, and experimental gene therapy. The review also discusses ethical and legal considerations, preventive strategies, and the future role of genomics and precision fetal medicine in improving maternal and fetal healthcare outcomes.

KEYWORDS: Fetal genetic disorders; Prenatal diagnosis; NIPT; Genetic counseling; Stem cell therapy; Gene therapy; Congenital anomalies; Thalassemia; Down syndrome; Precision fetal.

INTRODUCTION

Fetal genetic disorders—ranging from chromosomal anomalies like Down syndrome to single-gene conditions such as Thalassemia—represent a critical challenge in maternal-fetal medicine. These conditions are among the primary drivers of congenital abnormalities and

long-term disability globally. While our understanding of molecular biology has leaped forward, the ability to treat these disorders effectively before birth remains one of medicine's most difficult frontiers.

The global landscape of genetic care is marked by a sharp divide. In high-income nations, structured screening programs and breakthroughs like non-invasive prenatal testing (NIPT) have integrated seamlessly into standard care, significantly improving outcomes. However, the situation in India is more complex. Due to unique population genetics, there is a higher prevalence of certain inherited conditions, yet the healthcare system faces significant hurdles—namely, a lack of universal screening and a deep disparity in infrastructure between urban centers and rural villages. While India's prenatal care is advancing, the transition toward standardized genetic protocols is still a work in progress.

The backbone of modern management is early detection. Tools like advanced ultrasonography and amniocentesis provide families with the information needed for genetic counseling and informed decision-making. Beyond diagnosis, preventive measures—such as preconception counseling and folic acid supplementation—remain the most effective ways to lower the incidence of these conditions.

We are also entering a new era of "fetal therapy," where experimental treatments like in-utero stem cell transplants and enzyme replacement therapies are moving from theory to clinical trials. While these innovations are gaining traction globally, their presence in India is currently limited, highlighting a significant gap in healthcare equity.

This review provides a comparative analysis of how fetal genetic disorders are managed in India versus the rest of the world. By examining differences in screening strategies, diagnostic reach, and the availability of cutting-edge treatments, this study aims to identify the gaps in the Indian healthcare model and explore how to make advanced prenatal care more accessible to all.

Types of Fetal Genetic Disorder

Fetal genetic disorders are generally categorized by the specific nature of the genetic change. Understanding these categories is the first step toward accurate diagnosis, effective management, and informed prevention.

1. Chromosomal Disorders

These occur when there is an abnormality in the number or physical structure of chromosomes, often due to errors during cell division.

Down Syndrome (Trisomy 21): The most common chromosomal condition, caused by an extra copy of chromosome 21. It typically leads to intellectual disabilities and distinct physical features.



Turner Syndrome: Occurs only in females when one X chromosome is missing or partially deleted. It often results in short stature and heart defects.

Detection: These are often flagged during routine Non-Invasive Prenatal Testing (NIPT) or ultrasounds and confirmed through diagnostic procedures like amniocentesis.

2. Single-Gene (Monogenic) Disorders

These disorders are caused by a mutation in a single gene and follow clear inheritance patterns (autosomal or X-linked).

Thalassemia: A prevalent condition in India that affects hemoglobin production, leading to chronic, severe anemia.

Cystic Fibrosis: Caused by mutations in the CFTR gene, resulting in thick mucus that damages the lungs and digestive system.

Prevention: Carrier screening for parents is essential to identify risks before or during early pregnancy.

3. Multifactorial Disorders

These conditions do not stem from a single mutation but from a complex interplay between multiple genes and environmental factors.

Neural Tube Defects (NTDs): Such as spina bifida and anencephaly, which occur when the fetal spine or brain fails to close properly.

Risk Factors: These include maternal diabetes, certain medications, and a deficiency in folic acid.

Prevention: Taking folic acid supplements before and during early pregnancy can drastically reduce the risk of NTDs.

4. Rare Genetic Diseases

These are less common but often severe conditions that present significant diagnostic and therapeutic challenges.

Tay-Sachs Disease: A fatal neurodegenerative disorder caused by a specific enzyme deficiency that leads to progressive damage to the nervous system.

Osteogenesis Imperfecta: Also known as "brittle bone disease," it is characterized by fragile bones that break easily due to collagen defects.Indian healthcare model and explore how to make advanced prenatal care more accessible to all.

Risk Factors and Etiology of Fetal Genetic Disorders

The development of fetal genetic disorders is rarely tied to a single cause; rather, it is usually a complex interplay between biological inheritance and environmental influences. Identifying these risk factors is the first step toward effective prevention and early clinical intervention.

1. Advanced Maternal Age

One of the most established risk factors for chromosomal abnormalities is maternal age.

The Biological Link: As women reach age 35 and beyond, the risk of "nondisjunction" (errors in how cells divide) increases.

The Outcome: This aging process in the oocytes makes conditions such as Down syndrome and other aneuploidies significantly more likely.

2. Consanguineous Marriages (A Key Factor in India)

In many parts of India and the Middle East, marriages between close biological relatives remain a common cultural practice.

Genetic Impact: Consanguinity significantly raises the probability that both parents carry the same hidden mutation.

Specific Risks: This leads to a much higher incidence of autosomal recessive conditions, such as Thalassemia and various metabolic or enzyme deficiency disorders.

3. Environmental and Teratogenic Factors

External "teratogens"—agents that cause developmental malformations—can interfere with a fetus's genetic blueprint during critical stages of growth.

Chemical & Lifestyle Risks: Exposure to alcohol, smoking, and certain high-risk medications (like Thalidomide) can trigger structural defects.

Biological Risks: Maternal infections, such as Rubella, and exposure to high levels of radiation can cause lasting developmental delays or alter gene expression.

4. Family History and Inherited Mutations

A history of genetic conditions within a family is a primary red flag for future pregnancies.

Inheritance Patterns: Mutations may be passed down through autosomal dominant, recessive, or X-linked patterns (such as Hemophilia).

The Role of Screening: For families with a known history of conditions like Cystic Fibrosis, targeted carrier screening and genetic counseling are indispensable for managing future tools

DIAGNOSTIC TECHNIQUES

Prenatal diagnosis uses non-invasive methods like NIPT (>99% accuracy for trisomies) and ultrasound for screening, and invasive methods like amniocentesis or CVS for definitive, high-accuracy diagnosis. While NIPT is safe and highly sensitive for chromosomal abnormalities, invasive techniques remain the gold standard despite a small, \(\approx \) 0.1%–1% miscarriage risk.

1. Non-Invasive Diagnostic Methods (Screening)

These pregnancies. methods are safe and pose no risk to the fetus, used as first-line tools to identify high-risk.



Cell-Free DNA Testing (NIPT)

Analyzes fetal DNA in maternal blood, generally from 10+ weeks, with exceptional sensitivity (\(>99\%\)) for trisomies 21, 18, and 13.

Limitations: Screening only; false positives can occur, necessitating confirmatory testing.

Ultrasound

Detects structural abnormalities (e.g., neural tube defects, heart defects) via NT scan (\(11\text{--}14\) weeks) or anomaly scan (\(18\text{--}22\) weeks).

Limitations: Cannot diagnose microdeletions or specific genetic mutations.

2. Invasive Diagnostic Methods (Confirmatory):

These provide definitive diagnoses by sampling fetal cells, carrying a small procedural risk of miscarriage.

Amniocentesis

Performed between 15–20 weeks. Amniotic fluid is withdrawn to perform karyotyping or chromosomal microarray (CMA).

Risk: Low, roughly 0.11%–0.3% risk of pregnancy loss.



Treatment Approaches During Pregnancy:

Management of fetal genetic disorders varies significantly between India and developed countries, driven by disparities in infrastructure, technological capabilities, and healthcare policies.

1 India: Preventive and Diagnostic FocusIn India, prenatal management focuses on early detection, genetic counseling, and informed decision-making due to limited specialized fetal intervention centers.

Genetic Counseling: The primary approach following diagnosis. It is crucial for guiding parents on disease severity, recurrence risks, and management options, particularly for high-prevalence conditions like Thalassemia and Down syndrome.

Selective Termination of Pregnancy: A common outcome in cases of severe, structural, or lethal chromosomal abnormalities. This is governed by the Medical Termination of Pregnancy (MTP) Act, which permits termination in cases of significant fetal anomalies.

Symptomatic and Supportive Management: Focuses on monitoring fetal well-being, managing maternal complications, and planning for comprehensive postnatal care, rather than intrauterine therapy.

2. Developed Countries: Interventional Fetal MedicineDeveloped nations possess advanced fetal medicine centers capable of active, in-utero treatment for structural and, increasingly, genetic conditions.

In-utero (Fetal) Surgeries: Standardized procedures for conditions like Spina Bifida (myelomeningocele repair) and fetal anemia, which significantly improve neurological and functional outcomes.

Gene Therapy & Editing (Experimental): Emerging, highly specialized techniques utilizing viral vectors or CRISPR-based editing to correct genetic defects in utero. Research is targeting hemoglobinopathies and metabolic diseases, with preclinical studies demonstrating high efficiency[2]

Stem Cell Therapy: In-utero hematopoietic stem cell transplantation (IUHCT) is used in specialized settings for congenital blood disorders and immunodeficiencies. The immature fetal immune system allows for better engraftment with reduced rejection risk.[3]

Comparative study of treatment INDIA VS DEVELOPED COUNTRIES

STAGES	INDIA	DEVELOPED COUNTRIES
Postnatal Treatments	Available in selected hospitals,limited accessibility in rural areas.	Widely available with advanced genetics therapies (gene therapy, enzyme therapy).
Preimplementation Genetic Disorder	Limited to urban IVF centres sexually and less awareness.	Common in fertility clitics covered by insurance in some countries.
Prenatal Diagnosis	Widely practised (aminocentesis, ultrasound, NIPT) Ethical /legal debates on abortion.	Widely available , better access to counselling and legal framework for decision making.

ETICAL, LEGAL AND SOCIAL ISSUES

The Indian Context

Navigating Tradition and Regulation In India, the conversation around prenatal testing is heavily influenced by specific social challenges and strict legal boundaries.

The Legal Guardrails (PCPNDT Act)

The primary law here is the PCPNDT Act. Its main job is to stop sex-selective abortion and the misuse of technology. While it’s a vital tool for social justice, the heavy paperwork and

fear of legal trouble can sometimes make doctors hesitant, which may unintentionally slow down access for families who genuinely need diagnostic answers.

The Weight of Society

Decisions aren't usually made in a vacuum. In many communities, there is still a strong preference for male children and a significant stigma attached to disability. This means a mother's choice is often shared with—or pressured by—extended family and societal expectations, rather than being a solo medical decision.

The Awareness Gap

In rural areas, "genetics" is often a foreign concept. Many families aren't aware that carrier screening or counseling even exists, which unfortunately leads to late-stage diagnoses when options are much more limited.

Developed Countries

Autonomy and Access In many Western or developed nations, the focus shifts toward the individual and the "right to know."

The Power of Choice

The guiding stars here are Autonomy and Informed Consent. The system is built to empower the parents to make their own decisions based on clear, scientific data. Medical ethics focus on what the parents want for their future, backed by professional genetic counselors.

The Financial Hurdle: While the technology is cutting-edge, it's rarely cheap. Even in advanced systems, whether or not you get a specific high-end genetic test often depends on your insurance coverage or your ability to pay out-of-pocket, making "access" a matter of economics.

Reproductive Rights

There is generally a stronger legal framework supporting reproductive freedom. This allows parents to access diagnostic tools and make choices about the pregnancy within clear, established legal windows, focusing on the rights of the individual.

Prevention Strategies

A Proactive Approach Preventing fetal genetic disorders is a cornerstone of modern maternal and fetal medicine. Rather than simply reacting to a diagnosis, prevention focuses on

empowering families through early identification, genetic literacy, and public health support. By integrating these strategies, healthcare systems can significantly lower the incidence of life-altering congenital anomalies.

The Role of Carrier ScreeningCarrier screening acts as an early warning system. It identifies healthy individuals who carry a recessive gene for a specific disorder, often without any family history of the condition.

Spotlight: Thalassemia ScreeningIn regions like India, where Thalassemia is highly prevalent, screening before marriage or conception is a vital intervention.

The Genetic Risk: When both partners are carriers, there is a 25% risk in every pregnancy of having an affected child. Identifying this risk early allows couples to explore prenatal diagnosis and expert counseling.

Proven Success: Nations like Cyprus and Italy serve as global benchmarks; through mandatory and voluntary national screening programs, they have nearly eliminated the birth prevalence of severe Thalassemia.

Preimplantation Genetic Diagnosis (PGD): Prevention at the Embryonic StageFor couples known to be at high risk, PGD offers a way to prevent the transmission of genetic disorders before a pregnancy even begins. Used in tandem with in vitro fertilization (IVF), this technology allows for the genetic profiling of embryos.

How it Works: Only embryos confirmed to be free of specific chromosomal abnormalities or single-gene disorders (like Cystic Fibrosis or Huntington’s) are selected for transfer.

A Lifeline for High-Risk Families: This is particularly transformative for those struggling with recurrent pregnancy loss or those who already have a child with a genetic condition.

The Practical Hurdle: While medically revolutionary, PGD remains a "luxury" intervention in many developing nations due to high costs and the need for specialized laboratory infrastructure.

Public Health as a Preventive ToolMedical technology is only effective if the public knows it exists. Awareness is the bridge between scientific capability and community health.

The Power of Education: Campaigns focusing on the importance of Folic Acid supplementation have drastically reduced neural tube defects globally. Similarly, educating young adults in schools and colleges about genetic counseling helps destigmatize testing.

Rural Outreach: In countries like India, the challenge lies in "the last mile." Mobile health clinics and rural antenatal campaigns are essential to ensure that preventive care isn't just a privilege for those in urban centers.

FUTURE PERSPECTIVE

Looking Ahead: The Future of Fetal MedicineWe are standing on the brink of a revolution in prenatal genetics. The goal is shifting from simply identifying problems to actively preventing and treating them before a baby is even born. To get there, we need to make high-tech care accessible to everyone, embrace new genomic tools, and work together across borders.

Why India Needs National ScreeningIndia faces a significant challenge with inherited disorders, yet many families still lack access to basic testing. We need a unified national strategy to change this.

The Goal: Standardized guidelines that ensure every expectant mother—regardless of where she lives—has access to quality ultrasounds, carrier screening, and NIPT (Non-Invasive Prenatal Testing).The Impact: By catching risks early, we can significantly reduce the incidence of conditions like Thalassemia and ensure healthier outcomes for both moms and babies. True progress means ensuring a mother in a remote village gets the same quality of care as one in a major city.

Making Genomics Part of Everyday CareSoon, genetic testing won’t be a "special case" scenario—it will be a standard part of pregnancy care.What’s Coming: We’ll see tools like whole-exome sequencing and AI-driven data analysis become routine.

Why It Matters: Instead of waiting for symptoms to appear, doctors will use personalized risk models to predict and manage health issues with pinpoint accuracy. This moves us away from "waiting and seeing" toward precision medicine tailored to each baby’s unique DNA.

Global Teamwork for Rare DiseasesBecause rare diseases are, by definition, uncommon, no single country has all the answers. Solving these puzzles requires a global "brain trust."

The Strategy: By sharing genetic databases and running international clinical trials, we can speed up the development of cutting-edge treatments like gene editing (CRISPR) and stem cell therapy.

The Benefit: When developed and developing nations share their expertise and resources, breakthroughs happen faster, and life-saving tech becomes more affordable for everyone.

The Vision

Centers for Disease Control and Prevention. Birth defects and genetic disorders [Internet].

Atlanta: CDC; 2025 [cited 2026 May 9]. Available from: CDC Birth Defects﷯A New Standard of CareThe future of fetal medicine is built on four pillars:Testing that is safer and earlier (non-invasive diagnostics).Treating the baby while still in the womb (in-utero therapy).Healthcare built around your specific genetics.A global network of fetal therapy centers so that "rare" doesn't have to mean "untreatable.’’

CONCLUSION

Fetal genetic disorders are a major cause of congenital abnormalities and neonatal morbidity worldwide. Advances in prenatal screening and diagnostic technologies have improved early detection and management of conditions such as Down syndrome, Thalassemia, and neural tube defects.

This review highlights important differences between India and developed countries in prenatal genetic care. India mainly focuses on screening, genetic counseling, and selective termination, whereas developed countries have access to advanced fetal therapies including in-utero surgery, stem cell therapy, and experimental gene therapy.

Ethical, legal, and socioeconomic factors significantly influence prenatal care practices. Preventive strategies such as carrier screening, preimplantation genetic diagnosis, and public awareness programs play a vital role in reducing disease burden.

Overall, improving national screening programs, expanding access to advanced diagnostics, and integrating genomic medicine into antenatal care are essential for better maternal and fetal outcomes, especially in developing countries like India.

REFERENCES

1. Bianchi DW, Chiu RWK. Sequencing of circulating cell-free DNA during pregnancy. N Engl J Med., 2018; 379(5): 464-473.
2. Gregg AR, Skotko BG, Benkendorf JL, Monaghan KG, Bajaj K, Best RG, et al. Noninvasive prenatal screening for fetal aneuploidy. Genet Med., 2016; 18(10): 1056-1065.
3. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med., 2015; 372(17): 1589-1597.
4. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, et al. First-trimester or second-trimester screening for Down syndrome. N Engl J Med., 2005; 353(19): 2001-2011.
5. Wapner RJ, Martin CL, Levy B, Ballif BC, Eng CM, Zachary JM, et al. Chromosomal microarray versus karyotyping for prenatal diagnosis. N Engl J Med., 2012; 367(23): 2175-2184.
6. Carlson LM, Vora NL. Prenatal diagnosis: Screening and diagnostic tools. Obstet Gynecol Clin North Am., 2017; 44(2): 245-256.
7. Wilson RD, Audibert F, Brock JA, Carroll J, Cartier L, Gagnon A, et al. Prenatal screening, diagnosis, and pregnancy management of fetal neural tube defects. J Obstet Gynaecol Can., 2014; 36(10): 927-939.
8. Verma IC, Bijarnia-Mahay S, Puri RD. Public health approach to genetic disorders in India. Indian J Pediatr, 2021; 88(5): 428-434.
9. Colah R, Gorakshakar A, Nadkarni A. Global burden, distribution and prevention of β-thalassemias and hemoglobin E disorders. Expert Rev Hematol., 2010; 3(1): 103-117.
10. Deprest JA, Flake AW, Gratacos E, Ville Y, Hecher K, Nicolaides K, et al. The making of fetal surgery. Prenat Diagn., 2010; 30(7): 653-667.
11. Mackenzie TC, Flake AW. Fetal therapy for genetic diseases: Current status and future directions. Prenat Diagn., 2022; 42(9): 1120-1129.
12. Ormond KE, Laurino MY, Barlow-Stewart K, Wessels TM, Macaulay S, Austin J, et al. Genetic counseling globally: Where are we now? Am J Med Genet C Semin Med Genet., 2018; 178(1): 98-107.
13. Milunsky A, Milunsky JM. Genetic Disorders and the Fetus: Diagnosis, Prevention, and Treatment. 7th ed. Hoboken: Wiley-Blackwell, 2021.